Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 2

Pharmacologic properties of direct-acting anti-HCV agents in clinical development, modified by Liang and Ghany [71].

Property	NS3-4A protease inhibitors
Efficacy	High
Genotypic coverage	Narrow (second generation drugs have broader coverage)
Probability of drug resistance	High
Side effects	Substantial
Drug-drug interactions	Substantial